Corcept Therapeutics Incorporated (CORT)
NEUTRALFundamental
58
Preço
$123.06
Capitalização de Mercado
$13.04B
Parte 1 · Quanto vale a empresa
Visão Geral
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$831M
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$55M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$142M
Capital Próprio Total
$648M
Passivo Total
$189M
Rácio de Liquidez
2.86
Cobertura de Juros
-
Dívida/EBITDA
0.21
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$99.79
Preço Atual
$123.06
Margem de Segurança
-23.3%
Intervalo de Valor Justo
$64.86 - $134.71
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
293.43
ROE
15.4%
Rácio P/B
18.88
P/FCF
124.60
Margem Bruta
98.3%
ROIC
0.7%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
0.7%
WACC
8.0%
ROIC − WACC
-7.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (15)
- EPS shows upward trend
- Price CAGR 32.63%
- Gross Margin 98.3%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 8.4%
- Revenue Growth 5Y 16.6%
- Analyst Consensus 83% Buy
- Earnings Surprise avg 1684.0%
- Earnings Quality (OCF/NI) 1.99
Reprovado (9)
- ROIC 0.7%
- P/FCF 124.60
- P/B Ratio 18.88
- Operating Margin 0.8%
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 5.9%
- Net Margin Trend 6.6% vs 18.7%
- Piotroski F-Score 4/9
Indisponível (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A emitir novas ações, diluindo a participação
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, CEO & Director | 68 |
| Mr. Atabak Mokari | CFO & Treasurer | 48 |
| Mr. Sean Maduck | President of Endocrinology | 48 |
| Dr. William Guyer Pharm.D. | Chief Development Officer | 57 |
| Mr. Gary Charles Robb J.D. | Chief Business Officer & Secretary | 62 |
| Mr. Joseph Douglas Lyon | Chief Technology & Accounting Officer | 47 |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer | 65 |
| Ms. Amy Flood | Chief Human Resources & Communications Officer | - |
| Ms. Monica Tellado | President of Emerging Markets | 52 |
| Mr. Roberto W. Vieira | President of Oncology | - |
Risco de Auditoria
8
Risco do Conselho
5
Risco de Remuneração
7
Risco dos Direitos dos Acionistas
7
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for CORT, sourced from Markets Gazette.